Skip to main content
Log in

Beyond the biotech IPO: a brave new world

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: IPO windows and pricing.
Figure 2: Poor post-market performance.
Figure 3: Illiquid trading volumes.
Figure 4: The binary nature of public product-focused biotech plays.

References

  1. Mack, G. Nat. Biotechnol. 26, 960–961 (2008).

    Article  CAS  Google Scholar 

  2. Licking, E.F. Startup 2–18 (May 2009).

    Google Scholar 

  3. Geilinger, U. & Leo, C. Trade Sales of Biotechnology and Specialty Pharma Companies 2005–2008 (HBM Partners, Zug, Switzerland, 2009) http://www.hbmpartners.com/survey/Survey%202005-2008/HBM%20Pharma%20Biotech%20M&A%20Survey%202005-2008.pdf

    Google Scholar 

Download references

Acknowledgements

The author would like to thank A. Milne at Atlas Venture for her tireless data analysis and insightful support, as well as all the firms who helped contribute data sets.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

Atlas Venture is an investment firm focused on early-stage biotech. B.L.B. has a pecuniary interest in Atlas's success.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Booth, B. Beyond the biotech IPO: a brave new world. Nat Biotechnol 27, 705–709 (2009). https://doi.org/10.1038/nbt0809-705

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0809-705

  • Springer Nature America, Inc.

This article is cited by

Navigation